AstraZeneca PLC (LSE:AZN) Annual Report 2022
The latest annual report of AstraZeneca PLC (AZN) was published on 31 Dec 2022. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.
Key Statistics - AZN Annual Results
Amounts in USD
AZN Income Statement 2022 Annual Report
As per the latest Income Statement of AZN, the Net revenue increased by $6.934B (19%) compared to the previous period. The operating income in 2022 increased by $3.62B (68%). The net income as per the annual report was 3.29B which increased by $3.176B (2836%) compared to previous year.
Income Statement Report (2022/2021)
| 2022 | 2021 | |
|---|---|---|
| Total Revenue | 44.35B | 37.42B |
| Gross Profit | 35.73B | 27.62B |
| Operating Income | 8.96B | 5.34B |
| Income Before Tax | 2.5B | -265M |
| Net Income | 3.29B | 112M |
Balance Sheet - AZN 2022 Annual Report
Read further: AZN Balance Sheet Detailed Analysis
The latest balance sheet from annual result of AstraZeneca PLC showed the company reduced the cash on balance sheet by $-163.00M (-3%). The Net tangible assets of AZN on the balance sheet were at -22.09B which is $1.026B (4%) more than previous annual report. The total stockholder equity also decreased by $-2.231B (-6%) compared to previous reporting period.
Balance Sheet Statement Report (2022/2021)
| 2022 | 2021 | |
|---|---|---|
| Cash | 6.17B | 6.33B |
| Total Assets | 96.48B | 105.36B |
| Long Term Debt | 23.91B | 29.72B |
| Total Liabilities | 59.42B | 66.08B |
| Total Shareholder Equity | 37.04B | 39.27B |
| Net Tangible Assets | -22.09B | -23.12B |
Cash Flow Statement - AZN 2022 Annual Report
The 2022 annual cash flow statement of AstraZeneca PLC showed that the net income increased by $3.176B (2836%) compared to previous reporting period. Also the capital expenditure of AZN increased by $0 (0%).
As of 2022, the total cash from investing activities was -2.96B and total cash from financing activities was -6.82B.
Cash Flow Statement Report (2022/2021)
| 2022 | 2021 | |
|---|---|---|
| Net Income | 3.29B | 112M |
| Capital Expenditures | -1.09B | -1.09B |
| Dividends Paid | -4.36B | -3.86B |
| Total Cash From From Investing Activities | -2.96B | -11.06B |
| Total Cash From From Financing Activities | -6.82B | 3.65B |
AstraZeneca PLC Annual Report History
Income Statement
Income Statement history of AstraZeneca PLC (LSE:AZN)
| 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | |
|---|---|---|---|---|
| Total Revenue | 44.35B | 37.42B | 26.62B | 24.38B |
| Cost Of Revenue | 8.62B | 9.8B | 5.25B | 4.85B |
| Gross Profit | 35.73B | 27.62B | 21.37B | 19.54B |
| Research Development | 9.53B | 8.02B | 5.9B | 5.35B |
| Selling General Administrative | 17.47B | 14.46B | 11.59B | 11.44B |
| Non Recurring | - | - | - | - |
| Other Operating Expenses | -231M | -207M | -486M | -319M |
| Total Operating Expenses | 35.39B | 32.07B | 22.25B | 21.32B |
| Operating Income | 8.96B | 5.34B | 4.37B | 3.07B |
| Total Other Income Expense Net | -6.46B | -5.61B | -454M | -1.52B |
| Ebit | 8.96B | 5.34B | 4.37B | 3.07B |
| Interest Expense | -917M | -776M | -738M | -780M |
| Income Before Tax | 2.5B | -265M | 3.92B | 1.55B |
| Income Tax Expense | -792M | -380M | 772M | 321M |
| Minority Interest | 21M | 19M | 16M | 1.47B |
| Net Income From Continuing Ops | 3.29B | 115M | 3.14B | 1.23B |
| Discontinued Operations | - | - | - | - |
| Extraordinary Items | - | - | - | - |
| Effect Of Accounting Charges | - | - | - | - |
| Other Items | - | - | - | - |
| Net Income | 3.29B | 112M | 3.2B | 1.33B |
| Net Income Applicable To Common Shares | 3.29B | 112M | 3.2B | 1.33B |
Balance Sheet Statement
Balance Sheet Statement history of AstraZeneca PLC (LSE:AZN)
| 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | |
|---|---|---|---|---|
| Cash | 6.17B | 6.33B | 7.83B | 5.37B |
| Short Term Investments | 64M | 53M | 42M | 38M |
| Net Receivables | 9.92B | 8.79B | 5.65B | 5.18B |
| Inventory | 4.7B | 8.98B | 4.02B | 3.19B |
| Other Current Assets | 398M | 556M | 99M | 106M |
| Total Current Assets | 22.59B | 26.24B | 19.54B | 15.56B |
| Long Term Investments | 1.14B | 1.26B | 1.19B | 1.51B |
| Property Plant Equipment | 9.45B | 10.17B | 8.92B | 8.34B |
| Good Will | 19.82B | 20B | 11.85B | 11.67B |
| Intangible Assets | 39.31B | 42.39B | 20.95B | 20.83B |
| Other Assets | 4.17B | 5.3B | 4.28B | 3.47B |
| Deferred Long Term Asset Charges | 3.26B | 4.33B | 3.44B | 2.72B |
| Total Assets | 96.48B | 105.36B | 66.73B | 61.38B |
| Accounts Payable | 2.55B | 2.82B | 2.35B | 1.77B |
| Short Long Term Debt | 960M | 2.25B | 1.57B | 1.63B |
| Other Current Liab | 3.81B | 4.52B | 5.85B | 4.9B |
| Long Term Debt | 23.91B | 29.72B | 19.8B | 17.89B |
| Other Liab | 8.5B | 13.01B | 10.49B | 10.28B |
| Minority Interest | 21M | 19M | 16M | 1.47B |
| Total Current Liabilities | 26.29B | 22.59B | 20.31B | 18.12B |
| Total Liab | 59.42B | 66.08B | 51.09B | 46.78B |
| Common Stock | 387M | 387M | 328M | 328M |
| Retained Earnings | 3.12B | 3.64B | 6.44B | 5B |
| Treasury Stock | -1.62B | 111M | 881M | -143M |
| Capital Surplus | 35.16B | 35.13B | 7.97B | 7.94B |
| Other Stockholder Equity | -1.62B | 111M | 881M | -143M |
| Total Stockholder Equity | 37.04B | 39.27B | 15.62B | 13.13B |
| Net Tangible Assets | -22.09B | -23.12B | -17.17B | -19.37B |
Cash Flow Statement
Cash Flow Statement history of AstraZeneca PLC (LSE:AZN)
| 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | |
|---|---|---|---|---|
| Net Income | 3.29B | 112M | 3.2B | 1.33B |
| Depreciation | 5.18B | 4.04B | 2.83B | 2.71B |
| Change To Netincome | -2.49B | -272M | -1.65B | -802M |
| Change To Account Receivables | -1.35B | -961M | -739M | -898M |
| Change To Liabilities | 1.17B | 1.41B | 1.72B | 868M |
| Change To Inventory | 3.94B | 1.58B | -621M | -316M |
| Total Cash From Operating Activities | 9.81B | 5.96B | 4.8B | 2.97B |
| Capital Expenditures | -1.09B | -1.09B | -961M | -979M |
| Investments | -143M | 605M | 2B | 125M |
| Other Cashflows From Investing Activities | 60M | 54M | 87M | 274M |
| Total Cashflows From Investing Activities | -2.96B | -11.06B | -285M | -657M |
| Dividends Paid | -4.36B | -3.86B | -3.57B | -3.59B |
| Net Borrowings | -1.44B | 7.65B | 1.44B | -1.7B |
| Other Cashflows From Financing Activities | -1.05B | -178M | -101M | 4M |
| Total Cash From Financing Activities | -6.82B | 3.65B | -2.2B | -1.76B |
| Effect Of Exchange Rate | -80M | -62M | 12M | 5M |
| Change In Cash | -55M | -1.51B | 2.32B | 552M |
| Issuance Of Stock | 29M | 29M | 30M | 3.52B |